👀 Ones to watch: Undervalued stocks to buy before they report Q3 earningsSee Undervalued Stocks

Genmab AS (GE91y)

TradeGate
Currency in EUR
Disclaimer
21.60
0.00(0.00%)
Closed

GE91y Comments

Get ready for the ride!
ERs are out https://ir.genmab.com/financial-calendar
And no debt, $3B cash position, one of the most "trending" technologies around (bispecific antibodies) and an impressive outflux of new drugs via seemingly peerpoor (now that's a nice new word - you're free to use it;-) quality of research. I urge everyone to check it out - heres the Investor Presentation for Q22021 "https://ir.genmab.com/static-files/cac2e584-6554-4637-a367-a5d21abc51e0". Comp value 2day $30B, best realistic ;-) guess is double up in 3-4 yrs. Seriously.
Falling.. standard market reaction these days to good and solid reportings: crazy that is.. in spite of improved revenue outlook, 4 drugs on market (darazalex(need I say more?)+3 soon-to-become-blockbusters) + 1 prob-to-market-in-october (tisotumab vedotin, w Seagen) + 2 new drugs revealed (one of which: inclacumab - a Sickle Cell Disease treatment, outlicensed to Roche and further outlicensed to Global Blood Therapeutics, but none the less - w potential for BB).
32, 40 again soon
When :)
Luxus
Going 200 % up in the next 24-30 month
what about this stock?
The best upcoming medico company for cancer
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.